Pointe Capital Management LLC Increases Stake in Danaher Co. (NYSE:DHR)

Pointe Capital Management LLC grew its stake in Danaher Co. (NYSE:DHR) by 4.5% in the 3rd quarter, HoldingsChannel.com reports. The institutional investor owned 2,158 shares of the conglomerate’s stock after buying an additional 93 shares during the quarter. Pointe Capital Management LLC’s holdings in Danaher were worth $600,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in DHR. State of Alaska Department of Revenue lifted its stake in Danaher by 3.1% during the third quarter. State of Alaska Department of Revenue now owns 75,297 shares of the conglomerate’s stock worth $20,933,000 after purchasing an additional 2,265 shares during the last quarter. Financial Management Professionals Inc. lifted its stake in Danaher by 59.2% during the third quarter. Financial Management Professionals Inc. now owns 562 shares of the conglomerate’s stock worth $156,000 after purchasing an additional 209 shares during the last quarter. Frank Rimerman Advisors LLC lifted its stake in Danaher by 3.6% in the third quarter. Frank Rimerman Advisors LLC now owns 17,048 shares of the conglomerate’s stock valued at $4,740,000 after buying an additional 591 shares during the last quarter. First Bank & Trust purchased a new stake in Danaher in the third quarter valued at approximately $216,000. Finally, Wealth Enhancement Advisory Services LLC lifted its stake in Danaher by 1.0% in the third quarter. Wealth Enhancement Advisory Services LLC now owns 198,902 shares of the conglomerate’s stock valued at $55,299,000 after buying an additional 1,992 shares during the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Insider Activity

In other news, SVP Georgeann Couchara sold 952 shares of the company’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. This represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, Director Linda Filler sold 3,928 shares of the stock in a transaction dated Thursday, August 1st. The stock was sold at an average price of $279.50, for a total transaction of $1,097,876.00. Following the transaction, the director now directly owns 41,149 shares in the company, valued at approximately $11,501,145.50. This represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, SVP Georgeann Couchara sold 952 shares of the stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total value of $255,488.24. Following the transaction, the senior vice president now owns 4,212 shares in the company, valued at $1,130,374.44. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,059 shares of company stock worth $8,400,897 over the last three months. 11.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

DHR has been the subject of a number of research reports. KeyCorp boosted their price objective on Danaher from $290.00 to $310.00 and gave the company an “overweight” rating in a research note on Wednesday. Robert W. Baird dropped their target price on Danaher from $278.00 to $277.00 and set an “outperform” rating on the stock in a report on Wednesday. Wells Fargo & Company began coverage on Danaher in a report on Tuesday, August 27th. They issued an “equal weight” rating and a $280.00 target price on the stock. UBS Group dropped their target price on Danaher from $309.00 to $305.00 and set a “buy” rating on the stock in a report on Wednesday. Finally, Raymond James dropped their target price on Danaher from $310.00 to $300.00 and set an “outperform” rating on the stock in a report on Wednesday. Seven equities research analysts have rated the stock with a hold rating and thirteen have assigned a buy rating to the stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $287.28.

Danaher Price Performance

Danaher stock traded down $2.61 during trading hours on Friday, hitting $245.39. The stock had a trading volume of 3,226,925 shares, compared to its average volume of 2,743,044. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04. The stock has a market capitalization of $181.76 billion, a price-to-earnings ratio of 41.59, a PEG ratio of 4.49 and a beta of 0.83. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The stock’s fifty day moving average is $269.52 and its two-hundred day moving average is $260.42.

Danaher (NYSE:DHR) last issued its quarterly earnings data on Tuesday, October 22nd. The conglomerate reported $1.71 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.57 by $0.14. Danaher had a return on equity of 11.06% and a net margin of 16.94%. The business had revenue of $5.80 billion for the quarter, compared to the consensus estimate of $5.59 billion. During the same period in the prior year, the business earned $2.02 earnings per share. The business’s revenue was up 3.1% on a year-over-year basis. As a group, analysts predict that Danaher Co. will post 7.59 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Friday, October 25th. Stockholders of record on Friday, September 27th were given a $0.27 dividend. The ex-dividend date was Friday, September 27th. This represents a $1.08 annualized dividend and a dividend yield of 0.44%. Danaher’s dividend payout ratio is currently 18.31%.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.